Erectile dysfunction and impotence has a high prevalence among male hypertensive patients. Whether this relates mainly to specific drug side effects or to primary pathogenic disorders is unknown. In the present study 101 male patients from our outpatient hypertension clinic answered detailed questionnaires about hypertension and sexual function. Patients with perceived impotence were offered a thorough penile evaluation and examination performed by specialists in the urology department.
rectile dysfunction and impotence has a high prevalence among male hypertensive patients, compared with normotensive men. 1 Antihypertensive drugs such as methyldopa, 2 thiazides, 3,4 spironolactone, 5 guanethidine, 6 clonidine, 6 and certain ␤-blockers 2,4,6 have been stated to cause impotence as a specific drug side effect. Calcium channel blockers 7 and angiotensin converting enzyme (ACE) inhibitors 2 are often claimed to have less deteriorating effects on male erectile function. However, reports are often conflicting and inconsistent. 8 A primary pathogenesis such as atherosclerosis compromising penile arterial flow and worsened by blood pressure reduction itself could well be the main pathology. 8 In general, information about this topic is incomplete and fragmentary, as it is often based on case reports and uncontrolled studies, without a proper clinical evaluation/examination of penile functioning. 8 The main aims of our study were to assess prevalence of impotence in a well-described male hypertensive outpatient population, and, by thorough clinical examination, to classify impotence according to its possible etiologies.
PATIENTS AND METHODS
During a period of 4 months a total of 127 male hypertensive patients were seen at our hypertensive outpatient clinic. Twenty-five patients did not participate in the survey due to the following reasons: five, linguistic problems; three, poor general health; one, psychosis; one, dementia senilis; six, unwillingness; and nine, unknown.
The 101 participants answered a detailed questionnaire addressing duration of known hypertension, cardiovascular events and symptoms, drug treatment, smoking habits, alcohol consumption, diabetes, and sexual performance. Impotence was defined in the present study as an incapability to commence or complete sexual intercourse.
For each participant, a clinical examination including stethoscopy for carotid arterial murmurs and palpation for pulsation of arteries of lower extremities was made. Electrocardiogram, chest x-ray, serum cholesterol, serum creatinine, dipstick for proteinuria and glucosuria, and examination for hypertensive retinal eye background changes were performed. Hypertension was classified according to WHO stage I-III. Blood pressure was measured with mercury sphygmomanometer after 5 min rest in the supine position.
The mean values of three measurements were recorded at each visit to the outpatient clinic. Mean blood pressure (diastolic blood pressure ϩ 1/3 [systolic blood pressure Ϫ diastolic blood pressure]) was calculated from average blood pressure of the last two visits. Patients with perceived impotence were offered further examination in our impotence clinic. Patients were interviewed about the onset of impotence, the quality of penile tumescence and rigidity, libido, and sexual insufficiency. Clinical examination was made for penile malformations, testis atrophy, penile sensibility, cremasteric reflex, and femoral pulses. Patients without obvious etiology of impotence were examined with ultrasound Doppler of the penile arteries and, if accepted, also with a papaverine (60 mg) injection test, by which tumescence and rigidity were noted.
The papaverine test was also performed in patients who wished future papaverine treatment. As no single measurement can discriminate between arterial, venous, and neurogenic penile erectile dysfunction with certainty, classification of possible etiologies of impotence was based on patient history and clinical findings. Accordingly, arterial dysfunction was defined as the main etiology if the patient history pointed towards this and if atherosclerosis of the pelvic and femoral arteries was evident. In cases with no signs of atherosclerosis, arterial dysfunction was thought to be the main etiology if the papaverine test was positive or, if not performed, then the results of ultrasound Doppler were to be the final determinant. If the papaverine test was negative or other signs pointed towards venous leakage, the etiology would be classified as venous. Patients would then be offered examination with cavernosometry and cavernosography to support this diagnosis. Neurologic dysfunction was evaluated from the patient history of neurologic disorders and clinical examination. Cases with more than one possible etiology of impotence were classified as mixed.
Medication was recorded as current treatment, including drugs used up to 6 months before the survey. Impotence was classified as drug induced if patients ascribed onset of impotence to initiation of antihypertensive treatment.
Statistical calculations were based on nonparametric two-by-two frequency tables with use of Yates correction when proper, Fishers exact test, and Mann-Whitney rank sum test.
RESULTS
Twenty-seven of the 101 hypertensive male patients were found to be impotent. Nine were evaluated by urologists from the primary questionnaire only. Six had a penile arterial dysfunction and three had a mixed etiology (one, arterial/neurogenic; two, arterial/venous) as possible causes of impotence.
Eighteen patients were thoroughly examined at the impotence clinic. All were found to have penile arterial dysfunction. Accordingly, the prevalence of impotence in our hypertensive population was 27% (n ϭ 27, 24, arterial; three, mixed etiology). Patients with impotence were older than patients with normal potency (Table 1 , P Ͻ .009), and the prevalence of impotence was also correlated to age ( Table 2 ). The systolic blood pressure was significantly higher (P ϭ .046) among impotent patients, whereas no difference in diastolic or mean blood pressure was observed between the potent and impotent patients (Table 1) .
About 90% of the population studied had hypertensive disease according to WHO stage II or III. The prevalences of impotence according to each WHO stage I-III were 18%, 17%, and 47%, respectively, showing a significant increase of impotence in WHO stage III (Table 3 ). The single variable with the best correlation to impotence was intermittent claudication (P ϭ .001), followed by ischemic heart disease (P ϭ .005) ( Table 3) . With the exceptions noted earlier, no significant differences in the recorded variables were observed between impotent and potent patients.
The majority of the patients were treated with combination therapy consisting of two or more antihypertensive agents. No significant differences regarding the number of drugs used for each patient were observed between the impotent and potent patients. With the exception of the tendency towards more frequent ACE inhibitor treatment in the impotent (P ϭ .08), classes of antihypertensive drugs were evenly distributed between the impotent and potent patients (Table 4) . Twelve patients (44%) ascribed the onset of impotence to initiation of treatment with specific antihypertensive agents. All had impotence classified as an arterial dysfunction. The specific drugs associated with the occurrence of drug-induced impotence are shown in Table 5 . Patients with drug-induced impotence had significantly fewer arteries visualized with ultrasound Doppler, compared with impotent patients without suspected drug inducement (P ϭ .034, 2 4.492, 1 degree of freedom, Yates correction in effect). Otherwise the two groups were identical with respect to age, blood pressure, distribution of WHO stages, clinical atherosclerosis, and cardiovascular events and symptoms.
Thirteen patients were examined with the papaverine test and except one all had induced tumescence. Despite this only five patients were able to maintain sufficient rigidity.
DISCUSSION
Our results shows that impotence occurs frequently (27%) among hypertensive men visiting a hypertension outpatient clinic.
For comparison an epidemiologic crosssectional investigation of 272 randomly selected men living in the same area as our patients found an overall prevalence of impotence of 4%. 9 The data from this study 9 were based on a similar self-administered questionnaire, with the same definition of impotence as that used in our study. Comparisons for age decades are shown in Table 2 . These results correlate well with earlier findings. 1, 5 Not surprisingly, impotence was related to age, but the prevalence was also remarkably high (23% to 45%) in middle-aged patients (40 to 69 years of age).
Even though a well-recognized problem, only two patients (7%) were recorded as having impotence before our investigation. Nearly all felt great relief at the opportunity to describe the problem and have it explored in depth.
Impotence was caused mainly by arterial penile dysfunction (89%) related to the severity of hypertension and target organ damage, reflected in higher systolic blood pressure and WHO classification. The presence of intermittent claudication and ischemic heart disease was the major determinant of the latter relationship. Consequently it is likely that the penile arterial dysfunction in our hypertensive men was caused mainly by atherosclerotic changes in the penile arteries.
In 12 cases the patients ascribed impotence to the initiation of antihypertensive drugs. Whether this relates to a reduction in penile perfusion caused by lowering the blood pressure or by specific pharmacologic side effects cannot be determined from the present study with certainty. However, drug-induced impotence was associated with significantly fewer penile arteries visualized by ultrasound Doppler examination. This points towards a higher grade of penile arterial atherosclerosis. One could argue that these patients would be more vulnerable to blood pressure reduction and thereby more likely to experience impotence at the initiation of antihypertensive drug treatment. Also, the variety of agents incriminated in the occurrence of perceived drug-induced impotence speaks in favor of a mechanism related to blood pressure reduction rather than specific pharmacologic side effects.
Our results stress the need for careful evaluation of penile function and atherosclerotic manifestations when testing and comparing antihypertensive drugs for causing impotence. In general, patients with impotence should undergo a thorough penile examination to offer the best possible treatment, including vasoactive drug injections, penile vacuum devices, penile prostheses, or the newer oral (eg, Viagra, Pfizer, New York, NY) and intraurethral treatments.
CONCLUSION
Impotence is a major problem, with a high prevalence among hypertensive male patients. The main etiology is arterial dysfunction related to age, severity of hypertension, and target organ damage. Arteriosclerosis seems to be an important factor.
Patients often ascribe the onset of impotence to drug initiation. Our results pointed towards a mechanism related to blood pressure reduction rather than to specific drug side effects. Sexual performance should be dis- 
